Cognition Therapeutics received FDA feedback confirming psychosis in dementia with Lewy bodies (DLB) as an approvable outcome for their drug Zervimesine (CT1812). The FDA aligned with the company on key aspects of a Phase 3 pivotal trial, expected to begin mid-2027, enrolling DLB patients with psychosis symptoms. This trial will test Zervimesine against placebo over nine months, aiming to provide the first long-term treatment that slows hallucinations and delusions progression. The drug showed promising Phase 2 results, and the company plans to present more data soon at a major Alzheimer's conference.
ABI Research forecasts that industrial AI in software-defined automation will generate over $5 billion in revenue by 2035. Growth is driven by AI integration in SCADA/HMI, DCS software, Industrial PCs, and virtual controllers, enhancing flexibility a...
Man Group PLC filed a Form 8.3 disclosure revealing it holds a 1.57% interest in Senior Plc, primarily through cash-settled derivatives, totaling 6,613,314 securities as of June 23, 2026. This disclosure is part of regulatory requirements under the T...
The European Venture Fair (EVF) celebrates its 25th anniversary on September 9-10, 2026, in Zurich, gathering around 150 investors to discuss major themes like energy, fusion technology, physical AI, and AI's role in venture capital. The event featur...
Seven Boson Group Ltd. has launched its Sovereign AI Decision Intelligence service, allowing countries to deploy and govern advanced AI independently of foreign providers. This launch coincides with the EU's new legal mandate for AI sovereignty, mark...
Bunzl Canada's Cleaning & Hygiene division has achieved the Diamond status, the highest recognition from the Ontario Education Collaborative Marketplace (OECM) supplier program for 2025. This honor highlights Bunzl's consistent excellence in service,...
